When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Xeris Pharmaceuticals, Inc. is purchasing Strongbridge Biopharma in a stock swap and contingent value rights transaction.
Assuming approval of Strongbridge’s Recorlev, the combination will have three products on the market in 2022 while enjoying ~$50 million of merger synergies.
For the combination to realize significant upside, the market for rescue glucagon must expand in the manner Xeris anticipates.
A full investment analysis is presented in the paragraphs below.